¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(2ÀÏÂ÷) : 2023-05-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(2ÀÏÂ÷) : 2023-05-18
±³À°ÀÏÀÚ : 2023-05-18
±³À°Àå¼Ò : ÄÚ¿¢½º

±³À°ÁÖÁ¦ : 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023)(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  

À̸ÞÀÏ : webmaster@rheum.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ¿µ»óÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, °¡Á¤ÀÇÇаú

Âü¼®¿¹»óÀÎ : 1600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 49 ½Ã°£ 35ºÐ

¼¼ºÎ¼ö°­·á : 300,000¿ø  

ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀüÀÓÀÇ 300,000¿ø / Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø 160,000¿ø ÇöÀåµî·Ï: Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀüÀÓÀÇ 360,000¿ø / Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø 200,000¿ø

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101+102 08:00~08:40 Redefining Subcutaneous Infliximab in Rheumatic Disesase Á¤ÀçÇö(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 08:00~08:40 Value of remission in rheumatoid arthritis patients and the benefit-risk profile of upadacitinib Lai Shan Tam(The Chinese Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 08:00~08:40 Efficacy and safety of tacrolimus for rheumatoid arthritis À̽½±â(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 08:00~08:40 The role and expectations of Golimumab 100mg mono rheumatoid arthritis: Japanese experience with Golimumab Tsutomu Takeuchi(Keio Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103+104+105 09:00~09:30 The path I have taken for Korean Society of Rheumatology À¯´ëÇö(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103+104+105 09:30~10:00 Towards precision medicine in rheumatology: My career & decision ¹è»óö(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 09:00~09:30 Proper setting of ultrasound equipment ±èÀçÈÆ(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 09:30~10:00 Utilization of doppler test in rheumatology ±èÁ¶¾Æ(Á¶¼±´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 10:00~10:30 Evaluation of bones, cartilage, tendons and enthesitis using ultra sound ±èÇö¿Á(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 10:30~11:00 Utilization of ultra sound in Sjögren ¹ÎÈ«±â(°Ç±¹´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 11:00~11:30 Ultra sound use in spinal disease and neurological disease: Guided injection ÀÌâÈÆ(¿ø±¤´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 11:30~12:00 Intra-articular US-guided injection Á¤Á¾Çõ(¿ø±¤´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 09:15~09:45 B cell therapy for difficult lupus cases David Isenberg(Univ. College London)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 09:15~09:45 Cutaneous lupus Victoria Werth(Univ. of Pennsylvania)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 205A+B 09:15~09:45 Antiphospholipid syndrome Tatsuya Atsumi(Hokkaido Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 10:30~11:00 Systemic Lupus Erythematosus: Basic science Mary Crow(Hosp. for Special Surgery)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 11:00~11:30 Systemic Lupus Erythematosus Clinical science Paul Fortin(Université Laval)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 10:30~11:00 Emerging new diagnostic and therapeutic options in systemic sclerosis ±èÇö¼÷(¼øõÇâ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 11:00~11:30 Advances in therapeutic and diagnostic options for anti-neutrophil cytoplasmic autoantibody-associated vasculitis ÃÖÂù¹ü(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 11:30~12:00 Latest advances in the management of rheumatoid arthritis ±èÇظ²(°Ç±¹´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104+105 10:30~11:00 Interaction between stromal cells and immune cells: Past, present, and future ÀÌ»óÀÏ(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104+105 11:00~11:30 Pain in musculoskeletal diseases, friend or foe ±èÇö¾Æ(ÇѸ²´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104+105 11:30~12:00 Proteomics for the discovery of rheumatic diseases ±è¿ë±æ(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101+102 12:00~12:40 Taking advantage of the window of opportunity: Using targeted therapy in systemic lupus erythematosus Andrea Doria(Univ. of Padua)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 12:00~12:40 Impact of autoantibodies in rheumatoid arthritis treatment outcomes and rheumatoid arthritis associated co-morbidities Ronald Van Vollenhoven(Amsterdam UMC)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 12:00~12:40 Extension of rheumatic disease treatment area: Biosimilar`s role & position ±¸º»»ê(ÀÎÁ¦´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 12:00~12:40 The paradigm shift to selective COX-2 Inhibitor: How PRECISION trial and sub-analysis impact on non-steroidal anti-inflammatory drugs treatment ¼Ò¹Î¿í(ºÎ»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 13:00~13:20 Global epidemiology of systemic lupus erythematosus: Do we need more than just counts? Rosalind Ramsey-Goldman(Northwestern Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 13:20~13:40 Systemic lupus erythematosus disease burden from a patient perspective Lai Shan Tam(The Chinese Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 13:40~14:00 Access to health care ¹è»óö(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 14:00~14:10 Socioeconomic trends in outcomes of tertiary prevention among patients with systemic connective tissue disorders in Germany Patrick Brzoska(Witten/Herdecke Univ. Faculty of Health School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 14:10~14:20 ¡°Skin-deep resilience¡± in the black women¡¯s experiences living with lupus (BeWELL) study Kara W Chung(Tulane School of Public Health and Tropical Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 14:20~14:30 Prevalence of remission according to physician and patient and level of agreement in a real-world multicenter lupus registry José María Pego Reigosa(Hosp. Meixoeiro)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 13:00~13:20 Immune phenotype and its therapeutic application in systemic lupus erythematosus Yoshiya Tanaka(Univ. of Occupational and Environmental Health)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 13:20~13:40 The quest for end organ focused biomarkers in systemic lupus erythematosus Chandra Mohan(Univ. of Houston)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 13:40~14:00 Proteomics for urine biomarkers ±è°æ°ï(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:00~14:10 Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort Yanjie Hao(the Univ. of Melbourne)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:10~14:20 Urinary L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multiple ethnicities Huihua Ding(Shanghai Jiao Tong University School of Medicine affiliated Renji Hospital)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:20~14:30 Change in urinary biomarkers at three months predicts 1-year treatment response of lupus nephritis better than proteinuria Andrea Fava(Johns Hopkins Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 13:00~13:20 Lupus education for physicians and patients in a resource-limited setting Sandra Navarra(Univ. of Santo Tomas)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 13:20~13:40 Need for national educational tool ¼ºÀ±°æ(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 13:40~14:00 Patient perspectives on education using digital resources Á¤½Â¹Î(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 13:00~13:30 New initiatives of Asia Pacific League of Associations for Rheumatology (APLAR Academy) Debashish Danda(Christian Medical College Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 13:30~14:00 Lessons learned from the Japan College of Rheumatology International School Tsutomu Takeuchi(Keio Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 14:00~14:30 KCR¡¯s future directives for young rheumatologists ½Å±âö(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 13:00~13:30 Clinical Aspect of COVID-19 infection in patients with systemic autoimmune diseases ¹®¼öÁø(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 13:30~14:00 Alliance of T and innate immune cells via cytokine receptors in health and autoimmunity Insoo Kang(Yale Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 104 14:00~14:30 T cell immune responses against severe acute respiratory syndrome - Coronavirus Disease ½ÅÀÇö(Ä«À̽ºÆ®)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 13:00~13:20 Effect of complement factor H-related protein 5 in murine arthritis models ¼Õâ³²(À»Áö´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 13:20~13:40 The microbiome of the upper respiratory track in rheumatoid arthritis ÁÖ¿µºó(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 13:40~14:00 Glucocorticoid and infectious complication in rheumatic disease ¹ÚÁØ¿ø(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 14:00~14:20 Korean diagnosis-related groups (DRGs) payment system in rheumatic and musculoskeletal diseases ÃÖº´¿ë(¼­¿ïÀÇ·á¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 205B 14:30~15:30 Meet the Mentor 1 - Prof. George Tsokos George Tsokos(Harvard Medical School)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:30~14:35 Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity Dai Dai(Shanghai Renji Hosp. Shanghai Jiaotong Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:35~14:40 The transcriptional factor Pbx1 adjusts peripheral B cell homeostasis to constrain lupus autoimmunity Dai Dai(Shanghai Renji Hosp. Shanghai Jiaotong Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:40~14:45 Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice ±è¿µÀº(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:45~14:50 cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus Sarinya Kumpunya(Center of Excellence in Systems Biology)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:50~14:55 Type I interferon affects Th22 cell differentiation participated in the pathogenesis of lupus nephritis Haojie Xu(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 14:55~15:00 Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders Jerome Boyd-Kirkup(Hummingbird Bioscience)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 15:00~15:05 Trimeric oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease Mary Speir(Hudson Institute of Medical Research)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë A 15:05~15:10 Decreased natural killer t-like cells correlated to disease activity in systemic lupus erythematosus Yingni Li(Peking Univ. People¡¯s Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:30~14:35 Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients Romain Stammler(Cochin Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:35~14:40 The impact of high-risk antiphospholipid antibodies profile on major organ damage progression in systemic lupus erythematosus: CSTAR multiple prospective cohort study Yufang Ding(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:40~14:45 Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibodies associated adverse pregnancy outcomes: a based on a 13-year longitudinal cohort study Yin Long(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë B 14:45~14:50 Metabolomics analysis identifies biomarkers for APS and suggests potential new pathway for APS pathogenesis Yongjing Luo(Peking Univ.People)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:30~14:35 Clinico-pathological association of serum CD44 Level in Lupus Nephritis Patients Susan Yung(The Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:35~14:40 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study Ian M. Catlett(Bristol Myers Squibb)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:40~14:45 Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urine biomarker for Korean patients with Systemic Lupus Erythematosus ±èÁö¿ø(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:45~14:50 Anti-TCP1 antibody is the potential biomarker of Systemic Lupus Erythematosus (SLE) ÀÌ»ó¿ø(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:50~14:55 iC3b/C3 ratios more strongly correlate with SLE disease activity in African- Americans compared with Whites Alfred Kim((Washington Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 206 A+B 14:55~15:00 The neutrophil-to-C3 ratio (NC3R) was an inflammatory marker in the assessment of lupus nephritis and ocular vessel density in systemic lupus erythematosus patients Shuilian Yu(The Second Affiliated Hosp. of Guangzhou Medical Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:30~14:35 Effect of air pollutant exposure on disease activity of systemic lupus erythematous: A prospective longitudinal study from Korea °­ÁöÇö(Àü³²´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:35~14:40 Intervention to improve medication adherence among patients with systemic lupus erythematosus Kai Sun(Duke Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:40~14:45 Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy Margherita Zen(Univ. of Padua)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:45~14:50 Adverse childhood experiences and disease activity: The role of trauma in the black women¡¯s experiences living with lupus (BeWELL) study Kara W Chung(Tulane School of Public Health and Tropical Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:50~14:55 Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: Data from the SAR-COVID national registry Guillermo Pons-estel(Centro Regional de Enfermedades Autoinmunes y Reumáticas)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò ¹ÌÆ÷ë C 14:55~15:00 Comparison of clinical characteristics and outcomes in patients with systemic lupus erythematosus: a cross-national study Sung Sam Lim(Emory Univ. School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:30~14:35 Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide Porntip Intapiboon(Prince of Songkla Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:35~14:40 Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis: results from a real-world CSTAR cohort study Wei Bai(Peking Union Medical College Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:40~14:45 Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis: a prospective cohort study ½ÅÁ¤¹Î(ÇѸ²´ëÇб³ÀÇ·á¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:45~14:50 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab Ioannis Parodis(Karolinska Institutet)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:50~14:55 Predictors of renal relapse in Korean patients with lupus nephritis : over a 35-year period at a single center ÀüÈ£¿í(ÀÇÁ¤ºÎ¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 14:55~15:00 Predictors of renal flares in systemic lupus erythematosus: A post-hoc analysis of four phase III clinical trials of belimumab Alvaro Gomez(Karolinska Institutet)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 15:00~15:05 Does early complete remission preclude adverse outcomes in lupus nephritis? Dafna Gladman(Univ. Health Network Univ. of Toronto)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:30~14:35 Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort Yanjie Hao(The Univ. of Melbourne)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:35~14:40 Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients Bernardo Pons-estel(GLADEL (Latin American Group for the Study of Lupus))

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:40~14:45 Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus Alexandra Legge(Dalhousie Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:45~14:50 Association of latent tuberculosis infection with clinical and serological parameters in Systemic Lupus Erythematosus- a prospective observational study Gayathri Ms(Jawaharlal Institute of Postgraduate Medical Education and Research)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:50~14:55 Clinical significance of anti-La antibodies in a multicenter systemic lupus erythematosus cohort (RELESSER register) Alejandro Olive(Private clinical practice)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 14:55~15:00 Cluster Analysis and Subphenotype sTratification in Lupus Erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE) Shirley Chiu Wai Chan(Univ. of Hong Kong)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 15:30~16:00 T cell immunity in systemic lupus erythematosus Joe Craft(Yale Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 16:00~16:30 Lupus nephritis: Mechanisms of kidney damage George Tsokos(Harvard Medical School)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 16:30~16:40 EZH2 deficiency in B cells impairs plasmablast differentiation and ameliorates lupus-like disease in mice Amr Sawalha(Univ. of Pittsburgh)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 16:40~16:50 MEF2D (Mef2d) expression in CD4 T cells influences humoral autoimmunity by regulating follicular helper T cell differentiation and function ±è¿¹Áö(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 16:50~17:00 High genetic risk load for systemic lupus erythematosus in antinuclear antibody-positive individuals at the preclinical stage õ¼¼È¯(°æÈñ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 15:30~16:00 Clinical trials in evaluating new treatments for systemic sclerosis Dinesh Khanna(Univ. of Michigan)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 16:00~16:30 Optimal management of gastro-intestinal involvements in systemic sclerosis ÀÌÅÂÈñ(¼øõÇâ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 16:30~16:40 Risk of new-onset depression in patients with systemic sclerosis : A nationwide population-based study ¹®¼öÁø(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 16:40~16:55 Systemic sclerosis in Korea ÀÌÀººÀ(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 15:30~16:00 Animal models for rheumatic diseases Á¶¹Ì¶ó(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 16:00~16:30 Immune cell analysis for rheumatic diseases È«¼®Âù(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 16:30~17:00 Proteomics for autoimmune disease °­È£Ã¶(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 15:30~16:00 Ultrasound of the upper extremities ÀÌ°æ¾ð(¼øõÇâ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 16:00~16:30 Ultrasound of the low extremities Á¤ÀçÇö(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 16:30~17:30 Hands on courses of upper extremities - Shoulder ¹ÚÀ±Á¤(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 16:30~17:30 Hands on courses of upper extremities - Shoulder ¾È¼ö¹Î(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 16:30~17:30 Hands on courses of upper extremities - Wrist, Elbow ±èº¸¿µ(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 16:30~17:30 Hands on courses of upper extremities - Wrist, Elbow ¹Ú¿µÀç(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 17:30~18:30 Hands on courses of low extremities - Knee ³²º¸¶ó(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 17:30~18:30 Hands on courses of low extremities - Knee ÀÌâÈÆ(¿ø±¤´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 17:30~18:30 Hands on courses of low extremities - Ankle, Foot ¼­¿µ¼±(°æ»ó´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 209A+B 17:30~18:30 Hands on courses of low extremities - Ankle, Foot °íÁ¤Èñ(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 17:00~17:20 EULAR recommendations for management of systemic lupus erythematosus Elisabet Svenungsson(Karolinska Institutet and Karolinska Univ. Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 17:20~17:40 Treatment of systemic lupus erythematosus and lupus nephritis: Comparison of Asian and Western guidelines Chi-Chiu Mok(Tuen Mun Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 17:40~18:00 Cardiovascular disease risk management in systemic lupus erythematosus/antiphospholipid syndrome Thomas Dörner(Charite Universitätsmedizin Berlin)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 18:00~18:10 Responsiveness of the CLASI to alopecia and mucous membrane involvement: A retrospective study of prospectively collected data Victoria Werth(Univ. of Pennsylvania)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 18:10~18:20 Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus Chi-Chiu Mok(Tuen Mun Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ¿ÀµðÅ丮¿ò 18:20~18:30 Withdrawal of maintenance glucocorticoid versus other immunosuppressants among patients with Systemic Lupus Erythematosus in long term clinical remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial Aishwarya Gopal(Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER))

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 17:00~17:20 Deconvoluting janus kinase / signal transducers and activators of transcription building blocks in development and disease Lothar Hennighausen(Nat'l Institutes of Health)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 17:20~17:40 Type I interferon and T cell metabolism in systemic lupus erythematosus Marina Botto(Imperial College London)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 17:40~18:00 Extracellular DNA and DNases in systemic lupus erythematosus Boris Reizis(NYU Grossman School of Medicine)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 18:00~18:10 The innate immune checkpoint NLRP12 represses IFN signatures and attenuates the progression of lupus nephritis. Szu-Ting Chen(Nat'l Yang Ming Chiao Tung Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 18:10~18:20 Novel pathogenetic mechanisms mediated by dysregulation of TRIM21-STING-type I interferon axis in lupus ±è´Ù¼Ø(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101 18:20~18:30 Mechanistic interrogation of STAT1 gain-of-function syndrome provides new insights into human lupus pathogenesis Shaun Jackson(Seattle Children)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 17:00~17:20 Lupus in Africans - The past and the present Olufemi Adelowo(Lagos State Univ. Teaching Hosp.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 17:20~17:40 Overcoming the challenges of rheumatic diseases in Asian Pacific region Tsutomu Takeuchi(Keio Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 102 17:40~18:00 Global collaborations on clinical trial, practice, and education in pediatric rheumatology Angelo Ravelli(IRCCS Istituto Giannina Gaslini)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 205A+B 17:00~17:20 Disease activity and treatment target in systemic lupus erythematosus ¹æ¼Ò¿µ(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ÄÁÆÛ·±½º·ë 205A+B 17:20~17:40 Current therapies and changing perspective on managing lupus ¼­Ã¢Èñ(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 17:00~17:30 Recent advances in the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis Peter A. Merkel(Univ. of Pennsylvania)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 17:30~18:00 Application of the 2022 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis to Korean patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis ¾È¼º¼ö(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 18:00~18:10 Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to the 2022 ACR/EULAR classification criteria ÇÏÀå¿ì(¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 18:10~18:25 Metabolic syndrome in anti-neutrophil cytoplasmic autoantibody-associated vasculitis ¹ÚÇʱÔ(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 17:00~17:30 Meta-analysis for biomarker discovery ÀÌ¿µÈ£(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 17:30~18:00 Statistical methods for biomarker discovery ¹Ú¼­¿µ(Çѱ¹¹æ¼ÛÅë½Å´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 105 18:00~18:30 Electronic medical record data for biomarker discovery ÃÖÁ¾±â(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 101+102 18:30~19:10 A new chapter in lupus care: How can we improve long-term outcomes for patients? Masato Okada(Osaka Univ.)

±³À°½Ã°£ 05¿ù 18ÀÏ ±×·£µåº¼·ë 103 18:30~19:10 Tocilizumab for the treatment of systemic vasculitis ÀÌ»ó¿ø(¿¬¼¼´ëÇб³)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÌ»óÁöÁúÇ÷Áõ°ú ´ç´¢Ä¡·á ÃÖ½ÅÁö°ß ¿¬¼ö±³À° : 2023-05-18
´ÙÀ½±Û 2023³âµµ ´ëÇѽŰæ¿Ü°úÇÐȸ ´ë±¸°æºÏÁöȸ 2Â÷ ¿¬¼ö °­Á : 2023-05-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21212 °æ±â Á¦18ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ Çмú ½ÉÆ÷Áö¾ö : 2024-08-31 0 57 2024-07-02
21211 Àü³² 2024³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãß°è Microsurgery Workshop : 2024-08-31 0 54 2024-07-02
21210 ¼­¿ï ´ëÇѽŻý¾ÆÇÐȸ Á¦15Â÷ ±³À°¼¼¹Ì³ª : 2024-08-30 0 44 2024-07-02
21209 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À° : 2024-08-27 0 45 2024-07-02
21208 ¼­¿ï 2024³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2024-08-25 0 44 2024-07-02
21207 ¼­¿ï °³¿ø 18Áֳ⠱â³ä 2024 °­µ¿°æÈñ´ëÇб³º´¿ø ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-08-25 0 48 2024-07-02
21206 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ º¹ºÎ& ºñ´¢ ÃÊÀ½ÆÄ °Ë»ç ÀÔ¹®±³À°: °­ÀÇ ¹× ½Ç½À : 2024-08-25 0 48 2024-07-02
21205 ´ë±¸ Á¦3ȸ °è¸í´ëÇб³ µ¿»êº´¿ø ³»°ú ¿¬¼ö°­Á : 2024-08-25 0 48 2024-07-02
21204 °æºÏ Çѱ¹Ãµ½Ä¾Ë·¹¸£±âÇùȸ 2024 Post Graduate Asthma School (2ÀÏÂ÷) : 2024-08-25 0 42 2024-07-02
21203 ¼­¿ï Á¦32ȸ ´ëÇѺñ¸¸°Ç°­ÇÐȸ 2024 Ãß°èÇмú´ëȸ : 2024-08-25 0 34 2024-07-02
21202 ¼­¿ï Á¦14ȸ ¼Ò¾Æ°úÇб³½Ç ¼Ò¾Æ¾Ë·¹¸£±â, È£Èí±âÁúȯ ¿¬¼ö°­Á : 2024-08-25 0 45 2024-07-02
21201 ¼­¿ï ÇѾç´ëÇб³±¸¸®º´¿ø ¼Ò¾Æû¼Ò³â°ú ½Å»ý¾Æ, ¿µÀ¯¾Æ Why & How : 2024-08-24 0 39 2024-07-02
21200 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø º¸¼ö±³À° : 2024-08-24 0 38 2024-07-02
21199 ¼­¿ï ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ Á¦ 8ȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó : 2024-08-24 0 28 2024-07-02
21198 ¼­¿ï 2024³â ´ëÇѳ»ºÐºñÇÐȸ ´ëÇѼºÈ£¸£¸ó¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-08-24 0 46 2024-07-02
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷